Prognostic biomarkers in malignant lymphomas

References

• Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med 2008;168:469–476.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 2005;23:6351–6357.
   PubMed Web of Science ®Google Scholar
• Hartmann EM, Ott G, Rosenwald A. Molecular biology and genetics of lymphomas. Hematol Oncol Clin North Am 2008;22:807–823, vii.
   PubMed Web of Science ®Google Scholar
• Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334–336.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006;24:995–1007.
   PubMed Web of Science ®Google Scholar
• Hermine O, Haioun C, Lepage E, et al Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996;87:265–272.
   PubMed Web of Science ®Google Scholar
• Tang SC, Visser L, Hepperle B, Hanson J, Poppema S. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases. J Clin Oncol 1994;12:149–154.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Johnson NA, Ben-Neriah S, et al MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114:3533–3537.
   PubMed Web of Science ®Google Scholar
• Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood 2003;101:1220–1235.
   PubMed Web of Science ®Google Scholar
• Levine AJ, Hu W, Feng Z. The P53 pathway: what questions remain to be explored? Cell Death Differ 2006;13:1027–1036.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789–799.
   PubMed Web of Science ®Google Scholar
• Young KH, Leroy K, Moller MB, et al Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008;112:3088–3098.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Neumeister P, Goossens T, et al Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001;412:341–346.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313–2323.
   PubMed Web of Science ®Google Scholar
• Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 2005;87:163–208.
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Gascoyne RD, Dreyling M, Kluin P, Engert A, Salles G. Biomarkers and prognosis in malignant lymphomas. Clin Lymphoma Myeloma 2009;9:160–166.
   PubMedGoogle Scholar
• Rimsza LM, Leblanc ML, Unger JM, et al Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008;112:3425–3433.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Vose JM, et al A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003;101:2363–2367.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Montes-Moreno S, Roncador G, Maestre L, et al Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. Blood 2008;111:351–358.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Alizadeh AA, Rajapaksa R, Tibshirani R, Levy R. HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood 2003;101:433–440.
   PubMed Web of Science ®Google Scholar
• Natkunam Y, Zhao S, Mason DY, et al The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood 2007;109:1636–1642.
   PubMed Web of Science ®Google Scholar
• Pan Z, Shen Y, Du C, et al Two newly characterized germinal center B-cell-associated genes, GCET1 and GCET2, have differential expression in normal and neoplastic B cells. Am J Pathol 2003;163:135–144.
   PubMed Web of Science ®Google Scholar
• Choi WW, Weisenburger DD, Greiner TC, et al A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494–5502.
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Gaulard P, Leroy K, et al Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-Cell lymphoma treated with R-CHOP: A GELA Study. J Clin Oncol 2009;27:5573–5579.
   PubMed Web of Science ®Google Scholar
• de Jong D, Xie W, Rosenwald A, et al Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 2009;62:128–138.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Gascoyne RD. Gene expression signatures in follicular lymphoma: are they ready for the clinic? Haematologica 2008;93:982–987.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, et al Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555–4562.
   PubMed Web of Science ®Google Scholar
• de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005;23:6358–6363.
   PubMed Web of Science ®Google Scholar
• Hoglund M, Sehn L, Connors JM, et al Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer 2004;39:195–204.
   PubMed Web of Science ®Google Scholar
• Cheung KJ, Shah SP, Steidl C, et al Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood 2009;113:137–148.
   PubMed Web of Science ®Google Scholar
• O'Shea D, O'Riain C, Gupta M, et al Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood 2009;113:2298–2301.
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, et al Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159–2169.
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Ansell SM, Fredericksen ZS, et al Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood 2007;110:4455–4463.
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Wang S, Maurer MJ, et al Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 2007;109:5439–5446.
   PubMed Web of Science ®Google Scholar
• Farinha P, Masoudi H, Skinnider BF, et al Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169–2174.
   PubMed Web of Science ®Google Scholar
• Canioni D, Salles G, Mounier N, et al High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008;26:440–446.
   PubMed Web of Science ®Google Scholar
• Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007;13:5784–5789.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, et al CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–1423.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL. Jaffe ESPSASHTJVJW. WHO Classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. pp 1–439.
   Google Scholar
• Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283–4297.
   PubMed Web of Science ®Google Scholar
• Poppema S, van den BA. Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol 2000;10:345–350.
   PubMed Web of Science ®Google Scholar
• Ma Y, Visser L, Roelofsen H, et al Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood 2008;111:2339–2346.
   PubMed Web of Science ®Google Scholar
• Hsi ED. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment. Leuk Lymphoma 2008;49:1668–1680.
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121–127.
   PubMed Web of Science ®Google Scholar
• van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999;154:1685–1691.
   PubMed Web of Science ®Google Scholar
• Beck A, Pazolt D, Grabenbauer GG, et al Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasopharyngeal carcinoma: comparison with Hodgkin's disease. J Pathol 2001;194:145–151.
   PubMed Web of Science ®Google Scholar
• Ishida T, Ishii T, Inagaki A, et al Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006;66:5716–5722.
   PubMed Web of Science ®Google Scholar
• Ohshima K, Tutiya T, Yamaguchi T, et al Infiltration of Th1 and Th2 lymphocytes around Hodgkin and Reed-Sternberg (H&RS) cells in Hodgkin disease: Relation with expression of CXC and CC chemokines on H&RS cells. Int J Cancer 2002;98:567–572.
   PubMed Web of Science ®Google Scholar
• Niens M, Visser L, Nolte IM, et al Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol 2008;140:527–536.
   PubMed Web of Science ®Google Scholar
• Ma Y, Visser L, Blokzijl T, et al The CD4+CD26- T cell population in classical Hodgkin lymphoma displays a distinctive regulatory T cell profile. Lab Invest 2008;88:482–490.
   PubMed Web of Science ®Google Scholar
• Maggio E, van den BA, Diepstra A, Kluiver J, Visser L, Poppema S. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002;13(Suppl 1):52–56.
   PubMed Web of Science ®Google Scholar